Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02942771 · ClinicalTrials.gov registry record · Phase 1
A MAD Study of TT301/MW189 in Healthy Volunteers
A Phase 1 study of Healthy Adult Volunteers, sponsored by Linda Van Eldik.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT02942771: Completed Phase 1 study of Healthy Adult Volunteers, sponsored by Linda Van Eldik.
NCT02942771 is a Phase 1 study of Healthy Adult Volunteers that has completed, run by Linda Van Eldik. The registered enrollment target is 35 participants, above the 15-participant average among 4 other Healthy Adult Volunteers trials with a reported enrollment target (133% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02942771, a Phase 1 study of Healthy Adult Volunteers, has completed, sponsored by Linda Van Eldik.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Study is to find out whether an investigational drug is safe and well tolerated. MW189 is being studied as a possible short-term treatment for people with different types of brain injury. MW189 has previously been given to healthy human volunteers as a single dose, and there were no significant problems or bad effects in people who received the Study drug. However, before it can be tested in people with brain injury, it is important to test MW189 in healthy volunteers when given multiple doses.
Primary Outcome
The number of participants who experienced serious adverse events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 0.075mg/kg TT301/MW189
- DRUG 0.15mg/kg TT301MW189
- DRUG 0.25mg/kg TT301/MW189
- DRUG 0.30mg/kg TT301/MW189
Study Locations (1)
North Carolina
- Duke Clinical Research Unit 40 Duke Medicine Circle - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2018-06-04 |
| Phase | Phase 1 |
What the finished NCT02942771 record still lists
NCT02942771 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, above the 15-participant average among 4 other Healthy Adult Volunteers trials with a reported enrollment target (133% higher).
The record links to 1 condition, with Healthy Adult Volunteers appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.
NCT02942771 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02942771 about?
NCT02942771 is a clinical study titled "A MAD Study of TT301/MW189 in Healthy Volunteers". The purpose of this Study is to find out whether an investigational drug is safe and well tolerated. MW189 is being studied as a possible short-term treatment for people with different types of brain injury. MW189 has previously been given to healthy human volunteers as a single dose, and there were...
What is the current status of trial NCT02942771?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2017-03-20. Estimated completion is 2018-06-04.
What conditions does trial NCT02942771 study?
This clinical trial studies the following conditions: Healthy Adult Volunteers.
What interventions are being tested in trial NCT02942771?
The interventions under investigation include: Placebo (DRUG), 0.075mg/kg TT301/MW189 (DRUG), 0.15mg/kg TT301MW189 (DRUG), 0.25mg/kg TT301/MW189 (DRUG), 0.30mg/kg TT301/MW189 (DRUG).
Who is sponsoring clinical trial NCT02942771?
This trial is sponsored by Linda Van Eldik, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02942771 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects
COMPLETED · Phase 1
-
Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120
COMPLETED · Phase 1
-
4-methylpyrazole and Acetaminophen Metabolism
COMPLETED · Early Phase 1
-
Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI